Crossmark

Comparative efficacy and safety of Ranibizumab and Aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis

Crossref DOI link: https://doi.org/10.1186/s12886-026-04988-2

Published Online: 2026-06-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Xiaoqin

Yang, Yunfeng
License Information

Text and Data Mining valid from 2026-06-29

Version of Record valid from 2026-09-15
More Information

Article History

Received: 26 July 2025

Accepted: 29 May 2026

First Online: 29 June 2026

Declarations

Ethics, consent to participate, and consent to publish declarations: Not applicable.

Consent for publication: Not applicable.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below